Page 21 - Richard Kuhn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

IdentifySensors Biologics Moves New Pathogen Testing Platform To Commercialization Stage Electronic nanosensors are intended to replace PCR tests for many different pathogens News provided by Share this article Share this article CLEVELAND, May 13, 2021 /PRNewswire/  Nanotechnology firm, IdentifySensors Biologics, in partnership with Purdue University, announced that it has completed development of an all-new diagnostic technology platform that detects numerous pathogens, including COVID-19, using electronic nanosensors. The company has moved the research and testing into its commercialization stage, where engineers are finalizing designs for large-scale, roll-to-roll manufacturing. Check4 by IdentifySensors Biologics has moved its newly proven nanosensor technology to the commercialization stage. The company intends to produce a pathogen-testing platform that rapidly and accurately detects a wide range of infections, including COVID-19, Influenza, Hepatitis C, Lyme and HIV.

Joe mosbrookIdentifysensors biologicsRichard kuhnPurdue universityPurdue university institute of inflammationSensors biologicsரிச்சர்ட் குன்பர்‌ட்யூ பல்கலைக்கழகம்சென்சார்கள் உயிரியல்